Results 181 to 190 of about 8,073,410 (232)

Repeat kidney biopsy in patients with ANCA-associated vasculitis and suspected kidney relapse. [PDF]

Clin Kidney J
Braud P, Clech AL, Couvrat-Desvergnes G, Dimet J, Moreau A, Renaudin K, Benard L, Néel A, Ville S, Ronsin C.   +9 more
europepmc   +1 more source

The overlap of ANCA associated vasculitis with Sjögren's syndrome in elderly male patient: a case report and literature review. [PDF]

Front Med (Lausanne)
Zhu M, Zhu R, Zhu H, Jiang W, Jia Y, Zhang W, Qu Z, Lu K.   +7 more
europepmc   +1 more source

New-Onset ANCA-Associated Vasculitis in Pregnancy Successfully Treated With Rituximab: A Case Report and Literature Review. [PDF]

Kidney Med
Hajšelová Z, Krátký V, Hrušková Z, Kment M, Tesař V, Slanař O, Hartinger JM.   +6 more
europepmc   +1 more source

The Complement System in ANCA-Associated Vasculitis: Mechanistic Insights, Therapeutic Horizons, and Unmet Clinical Needs. [PDF]

Immun Inflamm Dis
Sunmboye K, Millan P.
europepmc   +1 more source

Addressing clinical challenges in ANCA-associated vasculitis with real-world evidence. [PDF]

Rheumatology (Oxford)
Jayne D.
europepmc   +1 more source

Correction to: The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis. [PDF]

Rheumatology (Oxford)
europepmc   +1 more source

Pathogenesis of PR3-ANCA associated vasculitis

Journal of Autoimmunity, 2008
Wegener's Granulomatosis (WG) is closely associated with antineutrophil cytoplasmic autoantibodies (ANCA), particularly those directed to proteinase 3 (PR3).
C G M Kallenberg, C G M Kallenberg
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Biologics for ANCA-Associated Vasculitis

Inflammation & Allergy-Drug Targets, 2014
The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are a group of necrotizing vasculitides with a potential fatal outcome. Conventional therapy is based on the use of glucocorticoids (GCs) and cyclophosphamide (CYC), which is associated with severe toxic effects and is unable to control the disease activity in some refractory ...
Murgia G, FIRINU, DAVIDE, MANCONI, PAOLO EMILIO, DEL GIACCO, STEFANO   +3 more
openaire   +3 more sources

The Future of ANCA-associated Vasculitis

Rheumatic Disease Clinics of North America, 2010
The introduction of cyclophosphamide for treatment and the detection of antineutrophil cytoplasmatic antibodies (ANCA) as a seromarker for ANCA-associated vasculitis (AAV) have been the most important milestones in the history of AAV. Nevertheless, there are still many issues to resolve to fully understand the pathogenesis of AAV and to improve patient
Julia U, Holle, Stefan, Wieczorek, Wolfgang L, Gross   +2 more
openaire   +2 more sources